Advantages of switching to elvitegravir/cobicistat/emtricitabine/ tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome  

作　　者：Lina Fan Lei Li Liying Gao Yue Hu Aiping Yu Defa Zhang Chunting Qiu Rong Huang Yue Wu Ping Ma 

机构地区：[1]Department of Infectious Diseases,Tianjin Second People's Hospital,Tianjin 300192,China

出　　处：《Chinese Medical Journal》2022年第22期2747-2749,共3页中华医学杂志（英文版）

基　　金：This work was funded by grants from the Tianjin Key Medical Discipline (Specialty) Construction Project (No. ZD02);the Tianjin Science and Technology Cultivation Project (No. RC20019)。

摘　　要：To the Editor:With recent advances in antiretroviral therapy(ART)regimens,many patients may benefit from switching drugs.The new combination drug,elvitegravir/cobicistat/emtricitabine/tenofovir(E/C/F/TAF),has been approved for use in people living with human immunodeficiency virus/acquired immune deficiency syndrome(HIV/AID[PLWHA])in China and has also been included within the scope of medical insurance.This single-tablet regimen provides a convenient,once-daily,treatment option for many PLWHA.E/C/F/TAF was shown to increase adherence to ART and decrease the risk of drug resistance and virological failure.[1–4]However,another study showed a higher level of several lipid parameters in patients with tenofovir alafenamide(TAF)-based therapy compared with tenofovir(TDF)-based therapy in treatment-naïve and-experienced adults.[5]In 2019,a phase IV clinical study of E/C/F/TAF was conducted at our Antiviral Treatment Center,allowing us to explore the virological and immunological responses during 12 months of follow-up after switching.We also explored the changes in renal function,liver function,and lipid parameters in PLWHA.

关 键 词：IMMUNODEFICIENCY DRUGS treatment 

分 类 号：R512.91[医药卫生—内科学]